In a phase I dose escalation trial, 40 adult patients with relapsed/refractory CD33-positive AML received GO until a maximum dose of 9 mg/m2 saturating almost all AML CD33-binding sites (92.2%) with an acceptable safety profile [24]. This evidence concerns the gene CD33 and acute myeloid leukemia.